178 related articles for article (PubMed ID: 9888698)
1. Immunocytokines: a promising approach to cancer immunotherapy.
Lode HN; Xiang R; Becker JC; Gillies SD; Reisfeld RA
Pharmacol Ther; 1998 Dec; 80(3):277-92. PubMed ID: 9888698
[TBL] [Abstract][Full Text] [Related]
2. Immunocytokines: a new approach to immunotherapy of melanoma.
Reisfeld RA; Becker JC; Gillies SD
Melanoma Res; 1997 Aug; 7 Suppl 2():S99-106. PubMed ID: 9578424
[TBL] [Abstract][Full Text] [Related]
3. Anti-cancer Therapies Employing IL-2 Cytokine Tumor Targeting: Contribution of Innate, Adaptive and Immunosuppressive Cells in the Anti-tumor Efficacy.
Mortara L; Balza E; Bruno A; Poggi A; Orecchia P; Carnemolla B
Front Immunol; 2018; 9():2905. PubMed ID: 30619269
[TBL] [Abstract][Full Text] [Related]
4. Recombinant immunocytokines targeting the mouse transferrin receptor: construction and biological activities.
Dreier T; Lode HN; Xiang R; Dolman CS; Reisfeld RA; Kang AS
Bioconjug Chem; 1998; 9(4):482-9. PubMed ID: 9667950
[TBL] [Abstract][Full Text] [Related]
5. Targeted cytokines for cancer immunotherapy.
Lode HN; Reisfeld RA
Immunol Res; 2000; 21(2-3):279-88. PubMed ID: 10852128
[TBL] [Abstract][Full Text] [Related]
6. What to do with targeted IL-2.
Lode HN; Xiang R; Perri P; Pertl U; Lode A; Gillies SD; Reisfeld RA
Drugs Today (Barc); 2000 May; 36(5):321-36. PubMed ID: 12861355
[TBL] [Abstract][Full Text] [Related]
7. Targeted interleukin-2 therapy for spontaneous neuroblastoma metastases to bone marrow.
Lode HN; Xiang R; Varki NM; Dolman CS; Gillies SD; Reisfeld RA
J Natl Cancer Inst; 1997 Nov; 89(21):1586-94. PubMed ID: 9362156
[TBL] [Abstract][Full Text] [Related]
8. Cytokine, chemokine, and co-stimulatory fusion proteins for the immunotherapy of solid tumors.
Khawli LA; Hu P; Epstein AL
Handb Exp Pharmacol; 2008; (181):291-328. PubMed ID: 18071951
[TBL] [Abstract][Full Text] [Related]
9. Elimination of established murine colon carcinoma metastases by antibody-interleukin 2 fusion protein therapy.
Xiang R; Lode HN; Dolman CS; Dreier T; Varki NM; Qian X; Lo KM; Lan Y; Super M; Gillies SD; Reisfeld RA
Cancer Res; 1997 Nov; 57(21):4948-55. PubMed ID: 9354462
[TBL] [Abstract][Full Text] [Related]
10. Suppression of human prostate carcinoma metastases in severe combined immunodeficient mice by interleukin 2 immunocytokine therapy.
Dolman CS; Mueller BM; Lode HN; Xiang R; Gillies SD; Reisfeld RA
Clin Cancer Res; 1998 Oct; 4(10):2551-7. PubMed ID: 9796990
[TBL] [Abstract][Full Text] [Related]
11. The present and future of immunocytokines for cancer treatment.
Gout DY; Groen LS; van Egmond M
Cell Mol Life Sci; 2022 Sep; 79(10):509. PubMed ID: 36066630
[TBL] [Abstract][Full Text] [Related]
12. Eradication of human hepatic and pulmonary melanoma metastases in SCID mice by antibody-interleukin 2 fusion proteins.
Becker JC; Pancook JD; Gillies SD; Mendelsohn J; Reisfeld RA
Proc Natl Acad Sci U S A; 1996 Apr; 93(7):2702-7. PubMed ID: 8610104
[TBL] [Abstract][Full Text] [Related]
13. Induction of persistent tumor-protective immunity in mice cured of established colon carcinoma metastases.
Xiang R; Lode HN; Dreier T; Gillies SD; Reisfeld RA
Cancer Res; 1998 Sep; 58(17):3918-25. PubMed ID: 9731503
[TBL] [Abstract][Full Text] [Related]
14. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin-2 in vivo: survival benefit and mechanisms of tumor escape in mice undergoing immunotherapy.
Mulé JJ; Ettinghausen SE; Spiess PJ; Shu S; Rosenberg SA
Cancer Res; 1986 Feb; 46(2):676-83. PubMed ID: 3484431
[TBL] [Abstract][Full Text] [Related]
15. Antibody-cytokine fusion proteins: Biopharmaceuticals with immunomodulatory properties for cancer therapy.
Hutmacher C; Neri D
Adv Drug Deliv Rev; 2019 Feb; 141():67-91. PubMed ID: 30201522
[TBL] [Abstract][Full Text] [Related]
16. Fractalkine (CX3CL1)- and interleukin-2-enriched neuroblastoma microenvironment induces eradication of metastases mediated by T cells and natural killer cells.
Zeng Y; Huebener N; Fest S; Weixler S; Schroeder U; Gaedicke G; Xiang R; Schramm A; Eggert A; Reisfeld RA; Lode HN
Cancer Res; 2007 Mar; 67(5):2331-8. PubMed ID: 17332365
[TBL] [Abstract][Full Text] [Related]
17. Immunocytokines are a promising immunotherapeutic approach against glioblastoma.
Weiss T; Puca E; Silginer M; Hemmerle T; Pazahr S; Bink A; Weller M; Neri D; Roth P
Sci Transl Med; 2020 Oct; 12(564):. PubMed ID: 33028706
[TBL] [Abstract][Full Text] [Related]
18. Improving the efficacy of antibody-interleukin 2 fusion proteins by reducing their interaction with Fc receptors.
Gillies SD; Lan Y; Lo KM; Super M; Wesolowski J
Cancer Res; 1999 May; 59(9):2159-66. PubMed ID: 10232603
[TBL] [Abstract][Full Text] [Related]
19. Immunocytokines for cancer treatment: past, present and future.
Neri D; Sondel PM
Curr Opin Immunol; 2016 Jun; 40():96-102. PubMed ID: 27060634
[TBL] [Abstract][Full Text] [Related]
20. Antibody-Cytokine Fusions: Versatile Products for the Modulation of Anticancer Immunity.
Neri D
Cancer Immunol Res; 2019 Mar; 7(3):348-354. PubMed ID: 30824549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
